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Summary
Recent research on Anorexia Nervosa (AN) and
Bulimia Nervosa (BN) has shown an increasing
understanding of the biological and physiological
abnormalities that underlie the development of an
eating disorder. Cultural pressures, individual and
family experiences, along with physiological and
genetic systems all appear to contribute to the
onset of these disorders. There is significant
evidence for genetic factors in the susceptibility of
AN/BN, however current research has focused on
the possibly of characterizing eating disorders as
being an autoimmune disease. Autoantibodies have
recently been discovered in patients with eating
disorders and could be affecting the biological
pathway of many hormones, specifically α -
melanocyte-stimulating hormone, by various
mechanisms.  Also these autoAbs have been
associated with physiological traits which also
have been proven to be symptoms of eating
disorders. The origin of these autoAbs remains to
be established. Yet childhood viral infections and
gut microflora may provide two explanations for the
creation of autoAbs. Future research needs to
examine the direction of causation, the underlying
mechanism of the immune response, and if this
could be contributed to the development of AN/BN.
Although there have been substantially advances in
the knowledge of eating disorders, the goal of
offering effective treatment to all patients remains
elusive.
Background on Anorexia Nervosa and Bulimia
Nervosa
History and Prevalence of Eating Disorders
Over the past 25 years Anorexia Nervosa (AN) and
Bulimia Nervosa (BN) have been recognized as eating
disorders and have received major attention among
both the general public and the research community
(1). AN and BN have both been characterized by
clinically significant disturbances in body image and
eating behavior (2). AN can be defined as a disorder in
which adolescents or young adults, mostly females,
become engaged in a relentless and successful pursuit
of thinness that usually results in serious weight loss
(1).  The core features of AN are cognitive and
disturbances in body image. These can include: feeling
fat even when emaciated, denial of seriousness of
one’s low weight, morbid fear of weight gain. AN also
has many physical consequences which can include:
failure to maintain a minimum adequate body weight
*This paper was written for BIO390 Independent Study taught by Dr.
Shubhik K. DebBurman.
less than 85% expected, and in girls and women,
amenorrhea, and can be engaged in the misuse of
laxatives, diuretics or enemas (2,3). BN is defined by an
overvaluation of weight and shapes in one’s sense of
self worth and behavioral symptoms of recurrent binge
eating, accompanied by inappropriate compensatory
behaviors (e.g. purging, fasting, excessive exercise,
use of drugs). AN was first recognized as a mental
disorder in the late 19th century; BN, after briefly being
considered a variant of AN in 1970, it was considered a
disorder by 1980. Therefore, given this short history, it
is not surprising that eating disorders are far less
researched than any other mental disorder (2).
Together both illnesses affect about 3% of
women over their lifetime.  However, BN, the more
common disorder, appears to be increasing in
incidence (1). Estimates of the prevalence of BN
behaviors have ranged from as low a 5% in family
practice adult samples to 20% in a population of college
females. BN in males has been reported as ranging
from 0% to 5% in college males (4). More importantly,
eating disorders all together have a prevalence of 10%
among any given population (1). Research has shown
that the average age of onset can range from 10 years
of age to 20, however 86% have reported the onset of
the illness by age 20. The duration of this illness can
also vary, yet 77% report the duration of the illness from
1 to 15 years. Nevertheless, what is important to note is
that only about 50% of people with an eating disorder
report ever being cured.
The Development and Treatment of Eating
Disorders
So the question remains how do people develop AN or
BN and why is it hard to stop?  Many AN/BN patients
report that their eating habits regain in the contest of or
immediately following a diet, and many continue to
restrict their caloric intake. Psychological factors also
seem to be critical in that patients frequently suffer from
depression, which has been linked to disturbances in
eating behavior. In addition, a variety of nonspecific
individual and familiar risk factor for psychiatric
disorders, such as a history of sexual abuse, seem to
increase an individuals chances of developing AN or
BN (1). More importantly, cultural influences play an
important role in the development of eating disorders.
Reports of AN and BN stem predominantly from the
industrialized world, where food is plentiful and thinness
(particularly for women) is equated with attractiveness
(2).
Yet how can we help people who develop
these eating disorders? Current treatments for AN are
aimed at normalizing body weight and correcting the
pre-occupation with weight loss. This intervention can
be achieved through admission to a hospital or a day-
treatment program where meals and exercise are
closely supervised and psychological counseling is
provided (1). Two approaches have been developed as
treatment for people with BN. The first approach is a
short term (4 to 6 month) form of physiological therapy
referred  to   as   cognitive  behavioral  therapy. In    this
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Figure 1: Biological Basis of Eating Disorders
AN and BN have been known to be sustained by physiological and biological processes. Serotonin, Leptin, and Cholecystokinin have been
recognized as three primary neurotransmitters and hormones involved in the regulation of food intake, fat storage, and eating behavior.
Changes in the concentrations of these can lead to the symptoms seen in eating disorders.
therapy, patients monitor their thoughts, feelings, and
help to cease binge-purge episodes and promote
regular eating. The second approach is the use of
antidepressant medications, such as Norpramin and
Prozac. These medications were initially demonstrated
as helping patients reduce binge frequency by helping
mood disturbances; however, only a minority of patients
have achieved full remission, and it is not known if there
will be a relapse in patients if medication is
discontinued (1, 2). Despite these advances in the
current treatments of AN and BN, the results are often
short term and do not focus on the long term
psychological disturbances and relapse is common.
Therefore, new interventions are needed.
Biological Basis of Eating Disorders
Due to the fact that AN and BN have prominent
psychological disturbances, many researchers have
questioned whether eating disorders have a biological
or genetic basis. Recent studies have shown
abnormalities in serotonin and leptin function (2). The
neurotransmitter serotonin is involved in physiological
systems, specifically mood disturbances, relevant of
AN. Increases in brain serotonin function lead to
reductions in food intake, and decreases in brain
serotonin function are associated with depression (3).
Additionally, leptin is a hormone secreted by fat cells
that appears to play an important part in the relation of
body fat stores. Consistent with the low body weight of
individuals with AN, research has shown at patients
with AN have low serum levels of leptin and these
increase with weight gain (1). Furthermore,
cerebrospinal fluid (CSF) levels have also been proven
to be low in underweight individuals, but appear to also
rise to normal levels if patients have long recoveries (4).
BN patients have also been linked to abnormal
serotonin function and this may contribute to the
persistence of binge eating. In addition, in some
patients with BN, may have an enlarged stomach and
have an excess amount of the satiety hormone
cholecystokinin (CCK) following a meal (Refer to Figure
1 for a more detailed description). These changes may
impede normal eating behavior (5). On the other hand,
familial factors also play a role in the development of
eating disorders. With regard to AN, a number of twin
studies have been performed in an attempt to
determine its heritability. Recent research has shown
that monozygotic (MZ) twins have 56% concordance
rate for developing AN whereas dizygotic (DZ) twins
have had 7% (6), however the statistics decrease if
these twins are reared apart. Therefore, it is predictable
that a substantial proportion of the predisposition to AN
could be genetic.
Molecular Basis of Eating Disorders
At a molecular standpoint, researchers have been
trying to link various genes to AB and BN. Many have
been identified including: 1) serotonin 2A receptor-
involved in regulation of food intake, 2) tryptpophan
hydroxlase- the rate limiting enzyme in serotonin
synthesis, lack of this gene is found in patients with AN,
3) dopamine and estrogen receptors- play a role in
amenorrhea, distortion of body image, and hyperactivity
seen in AN patients, 4) UCP 2ad UCP 3 proteins-
involved in control of energy expenditure and metabolic
adaptation during fasting, and 5) melanocortin 4
receptor gene, which has been involved in energy
balance, food intake, body weight regulation, and has
recently been involved in autoantibody research (7). A
few other genes such as leptin, agouti-related protein,
ESR1 and ESR2 genes (8), and neruopeptide Y have
also been studied for association with eating disorders
(9). Yet with all of this previous knowledge, genetic
research on eating disorders still remains in its first
steps. Many  gaps still remain in our understanding    of
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eating disorders such as what each gene does
specifically and does it interrupt the biological pathway?
More importantly can AN and BN be predicted
genetically or it is only a physiological disorder? These
questions still remain unknown as researchers are
trying to figure out how these genes influence the
development of an eating disorder. Current research
has been examining the possibility of characterizing AN
or BN as autoimmune diseases. In the following review
I would like to introduce the background regarding
autoimmunity by introducing the viral theory and
question where the origin of antibodies in AN or BN
patients.
Research Progress: Autoimmunity
What is an Autoimmune Disease?
Autoimmune disease can be defined as a disorder
caused by an autoimmune response, i.e., an immune
response directed to something in the body of the
patient. Since autoimmunity can affect any organ in the
body (including brain, skin, kidney, lungs, liver, heart,
and thyroid), the clinical appearance of the disease
depends upon the site affected. For many years,
medical professionals and researchers were skeptical
of the existence of autoimmunity since it seemed to
defy common sense. Why would a person develop an
immune response to himself or herself rather than to an
invading germ? Yet, once a person realizes that the
immune response is a powerful and complex biological
reaction, then one can assume, on occasion, the
reaction can misfire. These misfirings of the immune
system are the reason that autoimmune diseases
occur. Sometimes autoimmunity can be the initiating
cause of a disease. In other cases, autoimmunity can
contribute to, or exaggerate, a disease caused by
another factor. The presence of an autoimmune
response is signaled by the appearance of
autoantibodies (autoAbs) in a patient’s circulatory
system. Therefore, the demonstration of a particular
autoAbs usually constitutes the path to recognize an
autoimmune disease (10).
There are a few autoimmune diseases that
have already been identified by reasechers. For
example, Lupus is an autoimmune disease in which B
cells make autoAbs against histones and DNA.
Additionally, Insulin-Dependant Diabetes also has white
blood cells (T cells) of the body’s immune system attack
and destroys the pancreatic beta cells, halting the
production of insulin. Furthermore, extensive research
has been conducted regarding the autoimmune disease
Multiple Sclerosis (MS). In MS, the body produces T
cells that react against the myelin sheath, the “coating”
that covers and protects the nerve fibers in our CNS,
causing inflammation and scarring. Once this occurs,
the nervous system, which is the known “control center”
is unable to send messages, and that in turn has a
direct affect on brain signaling and movement all over
the body (11).
Based on previous knowledge in which eating
disorders have been characterized by having changes
in the concentrations of neuropeptides, researchers
have been examining possible underlying mechanism
causing this change. Currently, researchers have
identified autoAbs in patients that have eating disorders
and more importantly they have recognized the target
of these autoAbs.
New Research on Eating Disorders as a Possible
Autoimmune Disease
Fetissov and colleagues in 2002 were able to identify
antibodies against α-melanocyte-stimulating hormone
(α-MSH) and adrenocorticotropic hormone (ACTH) in
patients with AN and BN. In this study, they
hypothesized that because people with eating disorders
have trouble with the regulation of food intake and the
hypothalamic system is involved in energy intake and
expenditure, then it may be the target by autoAbs in
AN/BN patients, as shown in other neurological
disorders. After testing the sera of 57 patients with
eating disorders, they found that a significant
subpopulation of AN/BN patients have autoAbs that
bind to α-MSH or ACTH hormone. Another major
finding pointed to the involvement of stress (12). α-
MSH is a peptide found in the anterior pituitary gland
that is involved in appetite control and the stress
response (13), and ACTH is a hormone extracted from
the pituitary gland involved in stimulating the adrenal
glands to release glucocorticoids, which in turn affect
metabolism (14). Nevertheless, if these hormones are
being attacked by autoAbs, with what biological
pathway could this interfere?  First of all, these autoAbs
could interrupt signaling with food intake regulatory
neurons such as neuropeptide Y, which was already
recognized in AN/BN patients (15, 16). Second, they
could interfere with receptors, like MC4, which is
involved in the regulation of body weight (16). Lastly,
these autoAbs may block the overall function of α-
MSH/ACTH thereby affecting a person’s appetite and
metabolism. Therefore, all these explanations suggest
that if autoAbs react with neuropeptides responsible for
the central control of appetite and this further
characterizes the pathogenesis of eating disorders. Yet,
some researchers still view AN/BN as a mental
disorder, so can these autoAbs have an affect on
psychological traits?
In October 2005, Fetissov and colleagues
further studied the occurrence of autoAbs in AN and BN
patients using a sample from Estonia. In this
population, they found more autoAbs reacting with two
more neurohormones—Oxytocin (OT) and Vasopressin
(VP)—which are involved in the regulation of water
balance as well as in several motivated behaviors (17).
Therefore, they hypothesized that the levels of these
autoAbs many correlate with some psychological
problems found in AN and BN patients. Using the
Eating Disorder Inventory-test that is widely used to
assess the cognitive and behavioral characteristics
commonly found in individuals with AN and BN (18),
a long wi th autoAbs levels measured by
immunohistochemistry of human sera, they found
significant correlations between α-MSH autoAbs levels
and the total Eating Disorder Inventory 2-score.  Some
of these physiological traits that were correlated
include: drive for thinness, bulimia, ineffectiveness,
interpersonal distrust, ascetism, impulse regulation, and
social insecurity. The first three traits seem to be
consistent with the symptoms of both AN and BN
patients. Hence, autoAbs against α-MSH seem to be
interfering with the body through the melanocortin
system and could lead to the development of an eating
disorder (17).
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Figure 2: The Viral Theory
Recently AN/BN have been correlated to autoimmune disease. One possible explanation for the appearance of autoantibodies could be
due to a childhood infection. This can lead to the expression of autoantibodies that have been found in AN and BN patients.
Research as It Stands Today
Viral Theory Proposal: Why do Autoantibodies
Originate?
If autoAbs could be correlated to physiological traits,
then it is important to question where these antibodies
come from.  Yet researchers are only finding some
possible answers to this question by looking at
childhood diseases (i.e. The Viral Theory as seen in
Figure 2 could be a possible mechanism to why we are
seeing these new findings). Therefore one explanation
for the origination for these autoAbs could be their
recognition of certain hormones as foreign such as the
flu or some other form of bacteria. Another explanation
could be intestinal microflora found in the gut. Estonian
and Swedish populations seem to have significant
differences in the intestinal microflora compared to
other populations, which could trigger the development
of autoAbs in response to a foreign pathogen (19). The
intestinal route could be a main source of autoAbs
reacting with neuropeptides. However, a direct
comparison of autoAbs levels and gut microflora has
yet to be conducted. The viral theory does not have
enough support and needs to be examined further.
More importantly, the direction of causation still remains
to be established, as does the mechanism underlying
the exact immune response for each hormone. There
have been substantial advances in the underlying
knowledge of eating disorders in the last couple of
decades. However the goal of offering effecting
treatment to all individuals with eating disorders
remains elusive. Finding the underlying cause that
affects so many women everyday will be another step
forward in the finding a cure. With AN and BN being
among the most disabling and lethal of psychiatric
disorder (20), along with many physical attributes, it is
not hard to understand why researchers are having
such a difficult time finding the biological basis of the
origin of eating disorders. By further examining of
autoAbs and other genes it should provide important
insights into the genetic susceptibility to Anorexia
Nervorsa and Bulimia Nervosa
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